Research Papers:

Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients

Tangfeng Lv, Jiawei Zou, Hongbing Liu, Qin Shen, Zhenfeng Lu, XiaoJun Zhou, Xiaonan Wang and Yong Song _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:40643-40653. https://doi.org/10.18632/oncotarget.16539

Metrics: PDF 1059 views  |   HTML 1412 views  |   ?  


Tangfeng Lv1,2,3,*, Jiawei Zou1,*, Hongbing Liu2,3, Qin Shen4, Zhenfeng Lu4, XiaoJun Zhou4, Xiaonan Wang5 and Yong Song1

1Department of Respiratory Medicine, Jinling Hospital, Southern Medical University, Guangzhou, Nanjing, China

2Nanjing University Institute of Respiratory Medicine, Nanjing, China

3Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

4Department of Pathology, Jinling Hospital, Nanjing, China

5Department of Research and Development, Division of Precision Medicine, Geneseeq Technology Inc., Toronto, Ontario, Canada

*These authors have contributed equally to this work

Correspondence to:

Yong Song, email: yong_song6310@yahoo.com

Keywords: next-generation sequencing, early relapse, cancer-related genes, oncogene, surgical margins

Received: December 14, 2016    Accepted: February 23, 2017    Published: March 24, 2017


Stage I non-small cell lung cancer (NSCLC) patients experience a relatively high rate of recurrence, ranging from about 30-35%. We hypothesized that this elevated risk of recurrence is due to the presence of tumor cells at bronchial margins which was undetected by conventional light microscopy.Patients with clinical stage IA (T1N0M0) NSCLC were enrolled in this study,which included 8 early-relapse(ER) and 6 no-relapse(NR) patients. Primary tumor, bronchial margin,and normal lung tissues were collected and sent to a central site for targeted next-generation sequencing analysis. All of the patients were lung adenocarcinoma. Gene mutations were identified in all tumor tissue samples (100%).Oncogenic mutations were identified in 87.5%(7/8) bronchial margins of early relapse patients,whereas only 16.7%(1/6) no-relapse (NR) patient of marginal tissue had identified gene mutation.Additionally, concordance between primary tumor and bronchial margins was relatively high, with 4 of 8 (50%) ER patients having at least one identical mutation. Moreover, according to the gene mutation status in marginal tissue, 87.5% (7/8) of patients with at least one gene mutation in the bronchial margins had local recurrence or metastasis,whereas only 16.7% (1/6) of patients without any mutation detected had signs of relapse,the recurrence rate was significantly higher than that of the negative mutation margin group ((p (log-rank) = 0.023). The existence of oncogenic mutations in bronchial margins may represent occult residual tumor and elevated risk of recurrence in early stage NSCLC patients.Thus,assessing molecular status in bronchial margins may help identify patients who might benefit from extensive surgery or adjuvant treatment.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16539